Sck Activators
Sck Activators encompass a suite of chemical compounds that enhance the protein's activity through indirect but specific mechanisms within cellular signaling networks. For example, the activation of protein kinase C by Phorbol 12-myristate 13-acetate (PMA) can lead to the phosphorylation of Sck, thereby enhancing its role in signal transduction. Similarly, Forskolin's stimulation of adenylyl cyclase results in increased cAMP levels, which activate protein kinase A (PKA) and can lead to the phosphorylation and activation of Sck. The action of Epigallocatechin gallate (EGCG), a tyrosine kinase inhibitor, may reduce competitive phosphorylation, allowing Sck to become more active. LY294002, by inhibiting PI3K, may shift the balance of cellular signaling in a way that favors Sck activation, as pathways that are less inhibited by PI3K/AKT signaling may become more prominent. Inhibitors like U0126 and SB203580 target MEK and p38 MAPK, respectively, leading to an indirect increase in Sck activity by altering the cellular signaling landscape in favor of pathways that include Sck.
Continuing with the theme of indirect activation, Sphingosine-1-phosphate, by interacting with G-protein-coupled receptorsContinuing with the theme of indirect activation, Sphingosine-1-phosphate, by interacting with G-protein-coupled receptors, may initiate signaling cascades that activate Sck. PD 98059 and U0126, both MEK inhibitors, can potentially heighten Sck's activity by suppressing competing signaling routes, thus skewing the cell's signaling equilibrium towards Sck engagement. Intracellular calcium level modulators, Ionomycin and A23187, through their capacity to increase calcium concentrations within cells, can activate calcium-dependent signaling pathways that might involve Sck activation. Zaprinast contributes to this regulatory network by preserving cGMP levels, potentially enhancing Sck-related signaling. Lastly, Staurosporine, despite its broad kinase inhibition profile, may paradoxically foster Sck activity by selectively inhibiting kinases that negatively impact Sck function.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a diacylglycerol analog that activates protein kinase C (PKC). PKC can phosphorylate and activate Sck, which then engages in downstream signaling cascades. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin directly stimulates adenylyl cyclase, increasing intracellular cAMP levels, leading to the activation of PKA. PKA can phosphorylate Sck, enhancing its activity. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a tyrosine kinase inhibitor that can reduce competitive inhibitory phosphorylation, thereby potentially increasing the activity of Sck by relieving inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor; by inhibiting PI3K/AKT pathway, it can alter cellular responses that indirectly increase Sck activity by modulating its substrates or partners. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor; inhibiting p38 may lead to a compensatory increase in signaling pathways that involve Sck activation. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate engages with G-protein coupled receptors, which can lead to the activation of signaling pathways that include Sck as a component. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a specific inhibitor of MEK, which can lead to upregulation of pathways that indirectly activate Sck. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels, potentially enhancing Sck activity through calcium-dependent signaling pathways. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is another calcium ionophore that raises intracellular calcium levels, activating calcium-dependent proteins that may interact with Sck, thus enhancing its activity. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast inhibits phosphodiesterases, leading to increased cGMP levels, which may activate signaling pathways involving Sck. | ||||||